Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinical and sensorimotor gating effects of ketamine in normals
Autore:
Duncan, EJ; Madonick, SH; Parwani, A; Angrist, B; Rajan, R; Chakravorty, S; Efferen, TR; Szilagyi, S; Stephanides, M; Chappell, PB; Gonzenbach, S; Ko, GN; Rotrosen, JP;
Indirizzi:
Vet Affairs New York Harbor Hlth Care Syst, New York, NY USA Vet Affairs New York Harbor Hlth Care Syst New York NY USA York, NY USA NYU, Sch Med, New York, NY USA NYU New York NY USANYU, Sch Med, New York, NY USA Pfizer Inc, Groton, CT 06340 USA Pfizer Inc Groton CT USA 06340Pfizer Inc, Groton, CT 06340 USA
Titolo Testata:
NEUROPSYCHOPHARMACOLOGY
fascicolo: 1, volume: 25, anno: 2001,
pagine: 72 - 83
SICI:
0893-133X(200107)25:1<72:CASGEO>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
POSITRON EMISSION TOMOGRAPHY; BRAIN GLUCOSE-METABOLISM; NMDA RECEPTOR LIGANDS; PREPULSE INHIBITION; SCHIZOPHRENIC-PATIENTS; HEALTHY-VOLUNTEERS; ACOUSTIC STARTLE; NUCLEUS-ACCUMBENS; D-AMPHETAMINE; PREFRONTAL CORTEX;
Keywords:
prepulse inhibition; ketamine; schizophrenia; acoustic startle; sensorimotor gating; habituation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
79
Recensione:
Indirizzi per estratti:
Indirizzo: Duncan, EJ Vet Affairs Med Ctr, Mental Hlth Serv 116A, 1670 Clairmont Rd, Decatur, GA30033 USA Vet Affairs Med Ctr 1670 Clairmont Rd Decatur GA USA 30033 USA
Citazione:
E.J. Duncan et al., "Clinical and sensorimotor gating effects of ketamine in normals", NEUROPSYCH, 25(1), 2001, pp. 72-83

Abstract

The clinical similarities between PCP psychosis and schizophrenia have contributed importantly to the development of the glutamate hypothesis of schizophrenia, Sensory gating, as measured by prepulse inhibition of the acoustic startle reflex (PPI), is impaired in patients with schizophrenia, In animals, the noncompetitive NMDA antagonists PCP and ketamine disrupt PPI in away that resembles the defect seen in schizophrenia, The purpose of this work is to investigate the modulation of sensory gating in humans by subanaesthetic closes of ketamine. 16 healthy male subjects received a 60-min infusion of ketamine (0.5 mg/kg) or normal saline on two separate days in a randomized double-blind crossover design. Clinical ratings and PPI were none during the infusion on both days. Ketamine produced robust clinical effects. Dissociative symptoms as measured by the CADSS increased from 0 +/- 0.0 to29.3 +/- 14.3; negative symptoms (Affect Rating Scale) increased from 17.2+/- 0.8 to 24.8 +/- 3.1; and total BPRS scores increased from 18.3 +/- 0.8to 26.4 +/- 5.1. ANOVAs for these rating were all significant at the p <.000 level, although BPRS increases were not in the range seen in decompensated schizophrenic patients. The amplitudes of the startle responses to pulse-alone stimuli were not significantly different on ketamine and placebo days. Ketamine did not cause disruption in PPI as expected. On the contrary, in the first block of the PPI session ketamine significantly enhanced PPI (ANOVA; F=6.15, p =.026). These results indicate that the clinical effects ofketamine are not coupled with schizophrenic-like disruption of PPI in normal controls. [Neuropsychopharmacology 25:72-83, 2001] (C) 2001 American College of Neuropsychopharmacology. Published by Elsevier Science Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/11/19 alle ore 03:05:30